Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Convertible Debt (2017 - 2025)

Historic Convertible Debt for Dexcom (DXCM) over the last 9 years, with Q4 2025 value amounting to $1.2 billion.

  • Dexcom's Convertible Debt rose 31.53% to $1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.2 billion, marking a year-over-year increase of 31.53%. This contributed to the annual value of $1.2 billion for FY2025, which is 31.53% up from last year.
  • As of Q4 2025, Dexcom's Convertible Debt stood at $1.2 billion, which was up 31.53% from $1.2 billion recorded in Q3 2025.
  • In the past 5 years, Dexcom's Convertible Debt ranged from a high of $2.4 billion in Q3 2024 and a low of $1.2 billion during Q4 2022
  • Its 5-year average for Convertible Debt is $1.8 billion, with a median of $1.8 billion in 2021.
  • Over the last 5 years, Dexcom's Convertible Debt had its largest YoY gain of 10325.41% in 2024, and its largest YoY loss of 4918.25% in 2024.
  • Quarter analysis of 5 years shows Dexcom's Convertible Debt stood at $2.0 billion in 2021, then plummeted by 39.57% to $1.2 billion in 2022, then surged by 103.24% to $2.4 billion in 2023, then tumbled by 49.18% to $1.2 billion in 2024, then increased by 0.32% to $1.2 billion in 2025.
  • Its last three reported values are $1.2 billion in Q4 2025, $1.2 billion for Q3 2025, and $1.2 billion during Q2 2025.